Boothbay Fund Management’s Cytokinetics CYTK Stock Holding History

Boothbay Fund Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-160,300	Closed	-$10.6M	–	2327
2026 Q1	$10.6M	Buy	+160,300	New	+$10.2M	0.14%	120
2024 Q2	–	Sell	-26,700	Closed	-$1.87M	–	1591
2024 Q1	$1.87M	Buy	+26,700	New	+$2.07M	0.04%	530
2023 Q4	–	Sell	-41,400	Closed	-$1.22M	–	1714
2023 Q3	$1.22M	Buy	+41,400	New	+$1.38M	0.03%	677
2020 Q4	–	Sell	-337	Closed	-$730K	–	1264
2020 Q3	$730K	Buy	+337	New	+$7.88K	0.04%	529
2020 Q2	–	Sell	-496	Closed	-$585K	–	999
2020 Q1	$585K	Buy	+496	New	+$6.33K	0.05%	427
2017 Q4	–	Sell	-249	Closed	-$361K	–	730
2017 Q3	$361K	Buy	+249	New	+$3.4K	0.06%	332

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's CYTK Position: Q2 2026 in Review

Boothbay Fund Management reduced its Cytokinetics (CYTK) stake by 35% in Q2 2026, selling an estimated $2.61M and leaving 68,092 shares worth $5.8M. The position accounts for 0.08% of the portfolio, ranked #305.

Boothbay Fund Management first reported a position in CYTK in Q2 2018 and has held it in 18 quarters since. The position peaked at $6.88M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Boothbay Fund Management held 68,092 shares of Cytokinetics worth $5.8M as of Q2 2026.
Boothbay Fund Management sold 36,353 Cytokinetics shares in Q2 2026, an estimated $2.61M.
Cytokinetics made up 0.08% of Boothbay Fund Management's portfolio in Q2 2026, its #305 holding.
Boothbay Fund Management first reported a position in Cytokinetics in Q2 2018 and has held it in 18 quarters since.
Boothbay Fund Management's Cytokinetics position peaked at $6.88M in Q1 2026.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.